Skip to content
NBlaz – Lifestyle
Author:
Beam Therapeutics
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
March 25, 2026
←
Previous Page
1
2